You are in PORTALS Cardiac Imaging LipiScan IVUS Coronary Imaging System Receives CE Mark Approval

LipiScan IVUS Coronary Imaging System Receives CE Mark Approval

E-mail Print PDF


Cardiac imaging news

InfraReDx, Inc., a leading developer of intelligent cardiovascular diagnostic imaging technologies, will start commercialization of its LipiScan™ IVUS Coronary Imaging System throughout Europe after receiving the CE Mark approval.

With CE Mark approval, the LipiScan IVUS system is the only device available in both U.S. and Europe for the detection of the plaques that complicate stenting and believed to be the leading cause for most heart attacks.

Donald Southard, president and chief executive officer of InfraReDx, said: "Receipt of the CE Mark for the LipiScan IVUS system is an important regulatory milestone for InfraReDx as we advance our global commercialization strategy to make this novel product available to physicians worldwide. With the U.S. launch of the system well underway, we are already receiving tremendous interest from physicians in Europe and are in active discussions with prospective distributors of the product. We are currently finalizing our European marketing plan and expect to launch the LipiScan IVUS in select countries in the coming months."

The LipiScan IVUS Coronary Imaging system received U.S. Food and Drug Administration (FDA) approval in June 2010. The system includes the world's first and only cardiac catheter to combine intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy to help clinicians identify and characterize lipid core coronary plaques. In a single catheter pullback, the LipiScan IVUS provides physicians with a traditional IVUS image that clearly displays important structural parameters of the lesion, including its site, length, and degree of stenosis, in addition to evaluating stent placement. Moreover, the system performs spectroscopic analysis of optical data to produce a Chemogram™ map that determines the location of lipid core plaques and assesses their lipid core burden. Integrating and co-registering the Chemogram with IVUS provides key information to cardiologists during the cardiac catheterization procedure.

Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcenter, Erasmus University Hospital, Rotterdam, Netherlands, said: "The LipiScan IVUS system is an important new intravascular imaging tool that will be of immediate value to interventional cardiologists for the diagnosis and management of their patients. This impressive multimodality system provides an IVUS image of the vessel while simultaneously performing spectroscopic analysis for the accurate and immediate detection of lipid core plaques demonstrated to complicate stenting and suspected to cause most heart attacks. The Thoraxcenter is proud of its association with InfraReDx and the role we have played in the development of the LipiScan IVUS system and imaging catheter."

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.